Talecris Biotherapeutics, Inc., and the World Federation of Hemophilia (WFH) jointly announced on May 3, 2007, that the pharmaceutical company granted a $160,000 educational grant to support WFH’s global Laboratory Science Program. The overall goal of the program is to improve laboratory proficiency and expertise in the accurate and timely diagnosis of hemophilia, with an emphasis on developing countries.
Most of the funding is earmarked for the following components of the program:
The International External Quality Assessment Scheme (IEQAS) focuses on improving and standardizing laboratory diagnosis of hemophilia worldwide. Participating laboratories test a uniform blood sample to verify their procedures and diagnosis, helping identify those that need extra support. WFH collaborates in this effort with the World Health Organization (WHO) and the United Kingdom’s (UK) National External Quality Assessment Scheme for Blood Coagulation.
International Train the Trainers Course program brings head laboratory scientists from developing countries to the Royal Free Hospital in the UK for training on the latest techniques and scientific methodologies involved in the diagnosis of hemophilia and other bleeding disorders. The scientists then hold workshops to share their knowledge with other laboratory scientists in their country or region.
Laboratory Workshops facilitated by WFH in 2007 are designed to train laboratory specialists in developing countries around the world. Current workshops include sites in South America, Asia and the Middle East.
“The Talecris grant allows us to offer key components of our multifaceted Laboratory Science Program, and represents a solid example of a partnership with industry that will benefit people living with hemophilia around the world,”said Mark Skinner, WFH president.
Source: Talecris press release dated May 3, 2007